Asia-Pacific Cardiac Resynchronization Therapy (CRT) Market Size, Share & Trends Analysis Report By Product (CRT-Defibrillator, CRT-Pacemaker), By End User (Hospitals, Cardiac Centers, Ambulatory Surgical Centers, Other End Users) and By Country (China, Korea, Japan, India, Australia, Taiwan, South East Asia, Rest of Asia-Pacific) Forecasts, 2026-2034

Asia-Pacific Cardiac Resynchronization Therapy (crt) Market Size

The Asia-Pacific Cardiac Resynchronization Therapy Market size was valued at USD 2.34 billion in 2025 and is projected to grow from USD 2.55 billion in 2026 to reach USD 5.08 billion by 2034, growing at a CAGR of 8.99% during the forecast period 2026–2034.

Cardiac resynchronization therapy (CRT) is a treatment that assists the heart in beating at the correct rate. It employs a pacemaker to restore the heartbeat's normal timing pattern. The CRT pacemaker coordinates the synchronization of the heart's upper (atria) and lower (ventricles) chambers. It also regulates the synchronization between the heart's left and right sides.

The market for cardiac resynchronization therapy (CRT) was estimated to be worth USD 5.85 billion in 2021. One of the major trends accelerating market expansion is the rapid advancement of technology. The market is expanding due to sedentary lifestyle adoption, an aging population, and increased cardiovascular disease prevalence.

Highlights

• CRT-D dominates the market by Product.
• Hospitals dominate the market by End-User.
• Japan dominates the market by Country.

Market Dynamics

Asia-Pacific Cardiac Resynchronization Therapy (crt) Market Drivers

Increasing Geriatric Population

The target demographic for CRTs is people over the age of 60. The population driving the growth of the CRT market over the projection period is one with poor immunity levels and a propensity for chronic illnesses, such as cardiovascular disorders. The WHO predicts that between 2015 and 2050, the elderly population will double, rising from 12% to 22%. Because of this, it is anticipated that the lifetime of the general population will increase thanks to the most recent cardiac care procedures. The population percentage in each country over 65 in 2020 is shown in the chart below.

Asia-Pacific Cardiac Resynchronization Therapy (crt) Market Restraints

High Cost of Device

The demand for CRT devices is anticipated to be constrained by their high cost, particularly in developing and undeveloped economies. These gadgets are priced differently depending on the brand. Devices that are MRI-compatible cost more than those that are not.

Further restricting the market is that governments in many developing nations, including India, do not offer price caps on these gadgets. In India, a CRT-D implant costs roughly USD 16,500 on average. Depending on the facility and surgeon, this cost can range from USD 7,000 to USD 25,000.

This price is greater than the price range of USD 650 to USD 2,600 for automatic external defibrillators. In a similar vein, pacemakers cost between USD 3,000 and USD 4,000.

Therefore, the high price of CRT is expected to have a detrimental effect on the market.

Asia-Pacific Cardiac Resynchronization Therapy (crt) Market Opportunities

Government Initiatives

Several Asia-Pacific nations have implemented government initiatives to enhance healthcare infrastructure and encourage the adoption of cutting-edge medical technologies. As they support reimbursement policies and broaden access to CRT devices, these activities foster a favorable climate for the industry.

Governments in the Asia-Pacific region commonly work with industry stakeholders, academic institutions, and healthcare organizations to promote innovation, research, and development in the healthcare sector. Such partnerships enable information sharing, technology transfer, and funding opportunities, which can create more sophisticated CRT technologies and treatments. By encouraging product innovation and market expansion, these programs promote market growth.

Asia-Pacific Cardiac Resynchronization Therapy (CRT) Market Segmentation Analysis

By Product

The Asia-Pacific Cardiac Resynchronization Therapy (CRT) Market is segmented into CRT-Defibrillator and CRT-Pacemaker. CRT-Defibrillators combine cardiac resynchronization therapy with implantable cardioverter-defibrillator functionality, enabling ventricular synchronization while providing protection against potentially life-threatening ventricular arrhythmias. CRT-Pacemakers are primarily designed to improve ventricular coordination and cardiac function in eligible patients with heart failure and conduction abnormalities. Both products are used in advanced cardiac rhythm management, with product selection depending on patient condition, arrhythmia risk, clinical assessment, and treatment requirements. CRT-Pacemakers represent an important product category due to the growing need for cardiac resynchronization among patients with heart failure and conduction disorders across the region.

Increasing prevalence of cardiovascular diseases, rising incidence of heart failure, aging populations, improving access to advanced cardiac care, and technological advancements in implantable cardiac devices are supporting demand for both product categories. CRT-Defibrillators benefit from their combined resynchronization and defibrillation capabilities, while CRT-Pacemakers are supported by increasing diagnosis and management of heart failure and cardiac conduction abnormalities. Improvements in device miniaturization, battery performance, lead technology, remote monitoring, and implantation techniques are expected to strengthen adoption of advanced CRT systems across Asia-Pacific.

Request Customizationto receive a tailored report.

By End User

The Asia-Pacific Cardiac Resynchronization Therapy (CRT) Market is segmented into Hospitals, Cardiac Centers, Ambulatory Surgical Centers, and Other End Users. Hospitals represent a major end-user segment because CRT implantation requires specialized cardiovascular infrastructure, diagnostic equipment, trained specialists, and post-procedure monitoring. Cardiac centers provide specialized services for cardiovascular diagnosis, device implantation, rhythm management, and long-term patient follow-up, while ambulatory surgical centers are becoming relevant for selected procedures that can be performed in outpatient settings. Other end users include specialized healthcare facilities and medical institutions involved in cardiac rhythm management and cardiovascular care.

Growing demand for advanced cardiac treatment, increasing prevalence of heart failure and rhythm disorders, expansion of specialized cardiac facilities, and improvements in minimally invasive implantation techniques are supporting demand across end-user settings. Hospitals continue to benefit from their comprehensive cardiovascular infrastructure, while cardiac centers are gaining importance because of their specialized expertise and increasing focus on advanced rhythm-management procedures. Ambulatory surgical centers can benefit from the expansion of outpatient cardiac interventions, while remote monitoring and improved follow-up technologies are enhancing long-term management of CRT patients. Increasing healthcare expenditure and improving access to specialized cardiovascular care are expected to further support CRT adoption across Asia-Pacific.

Speak to an Analystto discuss market opportunities.

List of Key and Emerging Players in Asia-Pacific Cardiac Resynchronization Therapy (CRT) Market

• Abbott
• Boston Scientific Corporation
• Medtronic
• Biotronik SE & Co. Kg
• Microport Scientific Corporation
• LivaNova PLC
• Medico S.R.L.